Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

 
Note: ASCO and CAP are committed to keeping this guideline up to date. We are currently monitoring the literature to determine if a revision is needed or if we will reaffirm the recommendations.

Background

Note that recommendations in the 2007 American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) Guideline for Human Epidermal Growth Factor Receptor 2 (HER2) Testing have been reconciled with the April 2010 ASCO/CAP Estrogen (ER) and Progesterone Receptor (PgR) Guideline so that cancer specimens will be handled in a uniform manner for ER, PgR, and HER2 in breast cancer specimens.

In the Journal of Clinical Oncology, a joint letter to the editor by Elizabeth Hammond, MD, Daniel F. Hayes, MD and Antonio Wolff, MD, co-chairs of the ASCO/CAP guideline panels provides an important reminder of the intent of the ASCO and CAP guideline panel on HER2 Testing.

The letter also reconciles some pathology technical aspects with the recent guideline on Immunohistochemical Testing of Estrogen and Progesterone Receptor (ER and PgR) Testing in breast cancer.

Guideline Resources

Download the following:


Accreditation Requirements and Proficiency Testing (PT)

Accreditation checklist requirements regarding Er/PgR assay validation, specimen fixation, and proficiency testing are available to CAP accredited laboratories through e-LAB Solutions Suite or can be purchased by non-CAP accredited laboratories.

Meet PT requirements by ordering the appropriate program. Call the CAP customer contact center at 1-800-323-4040 option 1#.

Education

Gain the practical skills, tools, and techniques needed to ensure testing accuracy as well as compliance with ASCO-CAP Guidelines for HER2 and ER/PgR testing.

 

Feedback on Recommendations